Plausible mechanisms of action of SGLT2 inhibitor in hepatoprotection | Download Scientific Diagram
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism | SpringerLink
Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For? | American Society of Nephrology
SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report - Kidney Medicine
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure | Heart
SGLT2 Inhibitors: A New Class of Diabetes Medications
JCI Insight - Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care | Diabetes Technology & Therapeutics
IJMS | Free Full-Text | Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications - The Lancet
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition - ScienceDirect
SGLT2 Inhibitor-induced Euglycemic Diabetic Ketoacidosis - Renal Fellow Network
More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD - Kidney International
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits - American Journal of Cardiology
PLOS ONE: The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ...
Summary of Heart Failure Outcomes in SGLT2 Inhibitor Clinical Studies | Radcliffe Cardiology
SGLT2 Inhibitors – Diabetologia
SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease | Nature Communications
The role of SGLT2 inhibitors in Type 2 Diabetes | BJFM
SGLT2 Inhibitors in Heart Failure: DAPA-HF & EMPEROR Trials
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
